Virosomal Hepatitis A Vaccine (Strain RG-SB)

摘要: Synopsis Virosomal hepatitis A vaccine contains formalin-inactivated (strain RG-SB) antigen adsorbed on to immunopotentiating reconstituted influenza virosomes (IRIVs). IRIVs act as an adjuvant and may stimulate both the cell-mediated humoral immune responses antigens. In noncomparative studies, virosomal (500 radioimmunoassay units) has exhibited immunogenicity in adults children, inducing seroconversion almost all volunteers within 4 weeks (usually 2 weeks) of vaccination. Booster injections 12 months after initial dose increased anti-hepatitis virus (anti-HAV) antibody titres by 11- 39- fold. Studies up 3 years duration (with a booster vaccination 1 year) have shown high anti-HAV titres; protection against infection been estimated last for 8 12.5 unpublished report suggests that 68% vaccinees be protected ⩾30 years. In comparative produced lower than aluminium hydroxide-adsorbed HM175), but similar percentages seroconverted. The was 95% protective efficacy preliminary results randomised double-blind trial involving Nicaraguan children. The had better local tolerability HM175) studies. most common adverse effect pain or soreness at injection site. Thus, is highly immunogenic, demonstrated from report, appears relatively low incidence effects injection. final placement this prevention will determined it offers comparison other vaccines its relative acquisition costs.